Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
<p>Cell line and PDX genetics</p>
保存先:
類似資料
-
Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025) -
Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025) -
Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025) -
Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025) -
Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025)